Vical other research news

VICL (San Diego) presented laboratory data from 40 patients in a Phase I/II trial showing that the gene and protein were transferred and were detected for several weeks in more than 75 percent of patients.

T cells infiltrated tumors in 10 of 11 tested, and a cell-mediated immune response was detected in three of eight patient samples. Shrinkage of tumor was also found in some patients with advanced melanoma. ...